
Switzerland shows sustained growth of biotech sector
Capital investments in Swiss biotech companies reached the second-best amount ever with CHF3.33bn in the second year of the pandemic, according to...

Abliva decides on a SEK200m financing to fund Phase 2/3 study
Swedish Abliva is focussing on mitochondrial medicine, developing therapeutics for primary mitochondrial diseases, orphan indications of high unmet...

Biotalys’ first proteinbased biocontrol shows up in vineyards
Biotalys, the agricultural Technology (AgTech) company in Ghent (Belgium) and listed at EURONEXT (Euronext - BTLS) is devolping protein-based...

French Ipsen falls after Epizyme take-over announcement
Even if Ipsen succeeds in halving the losses at Epizyme Inc, this would reduce the group's profit by nine percent by 2024, Credit Suisse analysts...

Orphan drug developer Minoryx raises €51m
The Series C round was co-led by Columbus Venture Partners and Caixa Capital Risc, and supported by CDTI Innvierte, Fund+, Ysios Capital and other...

International Vaccine Institute – IVI – will locate its European office in Stockholm
The International Vaccine Institute, IVI, is establishing itself outside South Korea for the first time. Last week, the Swedish Parliament ratified...

GSK acquires Sierra Oncology for 1.9bn
GSK is paying $1.9 bn in cash ($55 per share) for the deal. This is a 39 per cent premium to the Sierra share price on 12 April and a 63 per cent...